Thursday, July 7, 2022
  • Login
Upgrade
The Southern African Times
  • Home
  • Southern Africa
  • Global
  • Business
    • African Start ups
    • African Continental Free Trade Area
  • Tech
  • Opinion
  • Sports
  • Lifestyle
    • Health
    • Culture
    • Food and Drink
    • Entertainment
  • SAT Jobs
No Result
View All Result
  • Home
  • Southern Africa
  • Global
  • Business
    • African Start ups
    • African Continental Free Trade Area
  • Tech
  • Opinion
  • Sports
  • Lifestyle
    • Health
    • Culture
    • Food and Drink
    • Entertainment
  • SAT Jobs
No Result
View All Result
The Southern African Times
No Result
View All Result
Home International news

J&J, Moderna sign deals with U.S. to produce huge quantity of possible coronavirus vaccines

by SAT Reporter
March 31, 2020
in International news, Just In
0
J&J, Moderna sign deals with U.S. to produce huge quantity of possible coronavirus vaccines
0
VIEWS

The U.S. government has cut deals with Johnson & Johnson (JNJ.N) and Moderna Inc (MRNA.O) and said it is in talks with at least two other companies to prepare them to produce massive quantities of coronavirus vaccines even before safe and effective ones become available.

There are currently no approved treatments or vaccines specifically for COVID-19, the respiratory disease that has killed more than 35,000 people and infected over 745,000 globally in just a few months. 

No vaccine is expected to be ready for use until at least 2021, as they must still be widely tested in humans before being administered to hundreds of millions, if not billions, of people to prevent infection.

On Monday, J&J announced a $1 billion deal with the U.S. government to create enough manufacturing capacity to make more than 1 billion doses of a vaccine, and its shares closed up 8% at $133.01. 

It has chosen a candidate but will not begin testing it in people until September. 

Moderna, which this month began very early tests of its vaccine candidate in people, also signed a deal with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. 

The arrangements are part of the federal government’s effort to encourage drugmakers to be able to produce massive amounts of COVID-19 vaccines even before any are proven to work. 

The J&J effort will be funded in part by about $420 million from BARDA. The agency told Reuters it also plans to spend an unnamed amount to ramp up manufacturing for Moderna’s COVID-19 vaccine candidate. 

Moderna shares rose 1.4% to $30.48. 

BARDA ultimately plans to support five or six experimental vaccine candidates, with the hopes of having two or three successful ones, BARDA director Rick Bright said in a phone interview. 

Experts have estimated it could be 12 to 18 months before a safe and effective vaccine wins regulatory approval. 

“Government and industry is working in unprecedented ways,” Bright said. The hope is to work “as quickly as possible and manufacture enough of it for us and the rest of the world in a very short timeframe.” 

The agency plans to take over manufacturing of Moderna’s vaccine candidate to enable the Cambridge, Massachusetts-based biotech to focus on testing it in larger trials. 

BARDA hopes to speed up the back end of the vaccine manufacturing process, which involves ensuring that they are made and packaged according to standards set by the U.S. Food and Drug Administration.

A LOT OF RISK INVOLVED’ 

There are dozens of coronavirus vaccines in development, according to the World Health Organization. But it is still not clear that people develop lasting immunity to this virus, or what it will take for a vaccine to be protective. 

“What you need to do is take an assessment of what the most likely candidates are and invest at risk in those,” said Seth Berkley, chief executive of the Global Alliance for Vaccines and Immunization (GAVI). 

The earlier you make that decision, the more likely you are to have manufacturing in place, but the less confident you are about whether the vaccine will work, Berkley said.

Typically, decisions on whether to move forward with a vaccine are made after safety trials and preliminary efficacy trials have been completed. 

J&J said it will begin human testing in September, with an eye toward having a vaccine ready under an emergency use authorization in early 2021. 

J&J Chief Scientific Officer Dr. Paul Stoffels told Reuters the company had to start ramping up manufacturing capacity now, even before it has a signal that its experimental vaccine candidate works. 

“That is the only option for us to get it on time,” Stoffels said of the early 2021 target. J&J hopes to have data proving its vaccine works by the end of this year. 

J&J has a manufacturing plant in the Netherlands that can make up to 300 million doses of vaccine, Stoffels said, but that “absolutely will not be sufficient for the world.” 

The company is also scouting for manufacturing plants in other parts of Europe and Asia capable of making the type of vaccine the company is working on. 

Stoffels said J&J’s vaccine will be based on the same technology used to make its Ebola vaccine, which has been widely used in people. The company believes it will prove safe. 

In lab studies, it has produced strong neutralizing antibodies to the virus – the type needed to make a successful vaccine.

Previous Post

Tech startups are joining Nigeria’s fight against coronavirus

Next Post

Tanzania confirms its first coronavirus death, health minister says

SAT Reporter

Related Posts

UK-funded low carbon technology programme calling for proposals in South Africa

UK-funded low carbon technology programme calling for proposals in South Africa

by SAT Reporter
July 6, 2022
JPMorgan warns oil prices could surge 240%
Business

JPMorgan warns oil prices could surge 240%

by SAT Reporter
July 4, 2022
15 African countries with the highest defense budgets in 2022
Just In

15 African countries with the highest defense budgets in 2022

by SAT Reporter
July 2, 2022
Key to Unlocking Major Investment in Africa – Better Data

Key to Unlocking Major Investment in Africa – Better Data

by SAT Reporter
July 2, 2022
Key takeaways from CBN’s new cybersecurity guidelines for Other Financial Institutions (OFIs) in Nigeria

Key takeaways from CBN’s new cybersecurity guidelines for Other Financial Institutions (OFIs) in Nigeria

by SAT Reporter
July 1, 2022
Next Post
Tanzania confirms its first coronavirus death, health minister says

Tanzania confirms its first coronavirus death, health minister says

Premium Content

Why the global methane pledge is a big deal for the climate

Why the global methane pledge is a big deal for the climate

November 1, 2021
Zimbabwe orders total lockdown from Monday to combat coronavirus

Zimbabwe orders total lockdown from Monday to combat coronavirus

March 28, 2020
West Indies’ golden T20I generation chase chance to cement legacy

West Indies’ golden T20I generation chase chance to cement legacy

October 18, 2021

Browse by Category

  • African Continental Free Trade Area
  • African Start ups
  • Algeria
  • Analysis
  • Angola
  • Asia
  • BOTSWANA
  • Botswana
  • Burkina Faso
  • Burundi
  • Business
  • Business
  • Cameroon
  • Central Africa
  • China
  • Climate Change
  • Climate Changev
  • Congo Republic
  • COVID 19
  • Culture
  • Democratic Republic of Congo
  • Eastern Africa
  • Egypt
  • Entertainment
  • Environment
  • Ethiopia
  • Europe
  • Fashion
  • Finance
  • Food
  • Food and Drink
  • Foods
  • Ghana
  • Global
  • Guinea
  • Health
  • Immigration
  • in Southern Africa
  • International news
  • Just In
  • Kenya
  • Lesotho
  • Libya
  • Life Style
  • Lifestyle
  • Malawi
  • Malawi
  • Mali
  • Markets
  • Middle East
  • Mozambique
  • Namibia
  • Nigeria
  • North Africa
  • Opinion
  • Politics
  • Rwanda
  • Senegal
  • Seychelles
  • South Africa
  • South Sudan
  • Sports
  • Startup Africa
  • STOCK EXCHANGE
  • Tanzania
  • Tech
  • Togo
  • Travel
  • Travel
  • Tunisia
  • Uganda
  • Uncategorized
  • West Africa
  • World
  • World
  • ZAMBIA
  • Zambia
  • ZIMBABWE
  • Zimbabwe

Browse by Tags

africa African business news Africa New Africa News african footballer African investments African manufacturing industry african markets African news African start-up banking Business China Classic Content currency Explore Bali Finance football Life Style Markets Market Stories Namibia news Nigeria oil and gas Oilandgas Opinion Pandemic Politics Premium reserve bank of Zambia Russia South Africa Southern African News sports Stay Home Travel United Stated Vaccine Work From Home Wuhan Zambia Zimbabwe Zimbabwe Harare Manufacturing Africa Employment creationn

WHO WE ARE

The Southern African Times is a regional bloc digital newspaper that covers Southern African and the world news. The paper also gives a nuanced analysis on news and covers a wide range of reporting which include sports, entertainment, foreign affairs, arts and culture.

Facebook Twitter Youtube Instagram Rss

Copyright © 2022 The Southern African Times | Powered by The Southern African Times

Privacy Policy

Terms and Conditions

  • Home
  • Southern Africa
  • Global
  • Business
    • African Start ups
    • African Continental Free Trade Area
  • Tech
  • Opinion
  • Sports
  • Lifestyle
    • Health
    • Culture
    • Food and Drink
    • Entertainment
  • SAT Jobs

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?